The Cutting Edge of Dermatology: New Data, Hot Topics, and Clinical Pearls | Ready to stay ahead in dermatology? Join the Derms on Drugs for a fast-paced, practical dive into the hottest new research and trends shaping our specialty.This week, we break down:Surprising long-term data comparing Dupixent and Rinvoq for atopic dermatitisThe future of autoimmune disease treatment: genetically modified T cellsWhat policies people actually support (and will pay for) to reduce skin cancer ratesJAK inhibitors for mucosal pemphigoid—what’s new, what works, and what to watch forThe latest on rising contact allergens: which ones are on the move and whyPacked with clinical pearls, practical tips, and a dash of humor, this episode is your shortcut to what’s new, what’s changing, and what you can use in practice right now.Don’t miss out—hit play for your weekly dose of dermatology insights!For links to all articles visit ScholarsinMedicine.com1. Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study2. Janus Kinase Inhibitors in the Treatment of Refractory Cicatrizing Conjunctivitis in Pemphigoid3. Long-Term Real-World Effectiveness of Dupilumab vs. Upadacitinib in early Treatment Responders with Atopic Dermatitis: Results from Central European Health Fund Registry4. Mid-term effectiveness, safety, and potential predictors of response of upadacitinib in patients with moderate-to-severe atopic dermatitis: a multicenter observational retrospective study5. Ivarmacitinib for Moderate to Severe Atopic Dermatitis in Adults and Adolescents6. Public preferences for skin cancer prevention policies: a discrete choice experiment in three European countries7. North American Contact Dermatitis Group Patch Test Results: 2021–2022